BIOCRYST PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$160.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$160.00K, a 131.13% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$406.00K, a 292.42% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$1.10M.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$506.00K, a 129.15% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$883.00K.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$416.00K, a 131.73% decline from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $1.31M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$160.00K 10-Q · filed 2026-08-05 | -$566.00K 10-Q · filed 2026-08-05 | -$1.67M derived: sum of 3 quarters · filed 2026-08-05 | -$2.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$406.00K 10-Q · filed 2026-08-05 | -$1.51M derived: sum of 2 quarters · filed 2026-08-05 | -$2.01M derived: sum of 3 quarters · filed 2026-08-05 | -$1.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.61M derived: sum of 2 quarters · filed 2026-02-26 | -$1.09M derived: sum of 3 quarters · filed 2026-08-05 | -$883.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$506.00K 10-Q · filed 2025-11-04 | $8.00K derived: sum of 2 quarters · filed 2026-08-05 | $219.00K 10-Q · filed 2025-11-04 | -$1.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $514.00K 10-Q · filed 2026-08-05 | $725.00K 10-Q · filed 2026-08-05 | -$647.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $211.00K 10-Q · filed 2026-08-05 | -$1.16M derived: sum of 2 quarters · filed 2026-08-05 | $575.00K derived: sum of 3 quarters · filed 2026-08-05 | $361.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2024-12-31 | -$1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $364.00K derived: sum of 2 quarters · filed 2026-02-26 | $150.00K derived: sum of 3 quarters · filed 2026-02-26 | -$416.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.74M 10-Q · filed 2025-11-04 | $1.52M derived: sum of 2 quarters · filed 2025-11-04 | $956.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$214.00K 10-Q · filed 2025-11-04 | -$780.00K 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | -$566.00K 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $1.31M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $110.00K 10-Q · filed 2024-11-05 | $215.00K derived: sum of 2 quarters · filed 2024-11-05 | $774.00K derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $105.00K 10-Q · filed 2024-11-05 | $664.00K derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $559.00K 10-Q · filed 2024-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |